Toll Free: 1-888-928-9744

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015

Summary


Global Markets Direct’s, ‘Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Myelosuppression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Myelosuppression and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Myelosuppression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Myelosuppression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chemotherapy Induced Myelosuppression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Myelosuppression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Myelosuppression
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Myelosuppression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chemotherapy Induced Myelosuppression Overview 6
Therapeutics Development 7
Pipeline Products for Chemotherapy Induced Myelosuppression - Overview 7
Pipeline Products for Chemotherapy Induced Myelosuppression - Comparative Analysis 8
Chemotherapy Induced Myelosuppression - Therapeutics under Development by Companies 9
Chemotherapy Induced Myelosuppression - Therapeutics under Investigation by Universities/Institutes 10
Chemotherapy Induced Myelosuppression - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Chemotherapy Induced Myelosuppression - Products under Development by Companies 13
Chemotherapy Induced Myelosuppression - Products under Investigation by Universities/Institutes 14
Chemotherapy Induced Myelosuppression - Companies Involved in Therapeutics Development 15
Biothera, Inc. 15
G1 Therapeutics, Inc. 16
Chemotherapy Induced Myelosuppression - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
calcitriol - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
G-1T28 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GZ-381 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Imprime PGG - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Chemotherapy Induced Myelosuppression - Recent Pipeline Updates 34
Chemotherapy Induced Myelosuppression - Dormant Projects 38
Chemotherapy Induced Myelosuppression - Product Development Milestones 39
Featured News & Press Releases 39
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 39
Jun 12, 2012: Biothera Discovers Biomarker For The Cancer Drug Imprime PGG 40
Jun 06, 2012: Imprime PGG Binds To Adaptive Immune Cells 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42
List of Tables

Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2015 7
Number of Products under Development for Chemotherapy Induced Myelosuppression - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Chemotherapy Induced Myelosuppression - Pipeline by Biothera, Inc., H1 2015 15
Chemotherapy Induced Myelosuppression - Pipeline by G1 Therapeutics, Inc., H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Chemotherapy Induced Myelosuppression Therapeutics - Recent Pipeline Updates, H1 2015 34
Chemotherapy Induced Myelosuppression - Dormant Projects, H1 2015 38 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify